EU Binds Sanofi to Commitments in Flu Vaccine Case Without Fine
The European Commission has decided to make Sanofi's commitments regarding the marketing of its flu vaccine Efluelda legally binding until March 2030, closing the case without finding an infringement or imposing a fine.
The European Commission has made Sanofi's commitments regarding the marketing of the flu vaccine Efluelda legally binding, thereby closing the antitrust case in Germany and France.
The Commission had preliminarily found that Sanofi might be a dominant company in the market, in a case concerning the competition between the Efluelda vaccine and CSL Seqirus's Fluad vaccine.
The Commission did not establish any infringement and did not impose a fine, with the commitments remaining in effect until March 2030 and including the appointment of a monitoring trustee.
The case was registered under number AT.40998.
What Do These Terms Mean?
Binding Commitments: Obligations offered by a company to a regulatory authority to address competition concerns, which become legally binding in exchange for closing the case.
Market Dominance: A company's control over a specific market to an extent that allows it to act independently of competitors and customers.
Monitoring Trustee: An independent entity that monitors the company's compliance with implementing its commitments.
Antitrust: Laws that prevent practices that restrict competition and harm consumers.
Weekly Newsletter
Read between the lines before everyone else. Decode the most important economic, tech, and decision-maker movements in the region.. in 5 minutes every Saturday.
